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patients with ulcer bleeds exhibiting high risk stigmata at
time of endoscopy. We assessed the cost-effectiveness of
starting an IV infusion of pantoprazole (80-mg bolus 
followed by 8mg/hr for 3 days) for high risk, non-variceal
ulcer lesions after therapeutic endoscopy had been 
performed.
METHODS: A decision analysis was conducted by cre-
ating a decision tree model in Data 3.5. The assumptions
of probabilities and costs were derived from the litera-
ture, a local cost database, and a national Registry of
patients with Upper Gastrointestinal Bleeding undergoing
Endoscopy (RUGBE). Efﬁcacy was the proportion of
patients with an episode of rebleeding. Both threshold
and sensitivity analyses were conducted. The time horizon
was 30 days following hospital admission.
RESULTS: It was estimated that hospitalization costs 
for patients with uncomplicated and complicated ulcer
bleeds were respectively CDN$1546.08 and $3275.63
per patient. Over the range of probabilities covered by
the 95% conﬁdence interval assigned to the rebleeding
rate, the optimal strategy was the use of IV PPI infusion
versus non-use. The IV PPI strategy exhibited higher
effectiveness (17% decrease in rebleeding) at lower cost
($67 less per hospitalized patient). The estimates were
robust across a wide range of clinically relevant variables.
Assumptions about hospitalization costs had the greatest
effect on the decision to start/not start the IV PPI.
CONCLUSIONS: Based on the assumptions of our
model, the most cost-effective approach is to start an IV
PPI infusion for a patient with a high-risk ulcer bleed
having undergone urgent endoscopic therapy.
PGI6
EFFECT OF POSTOPERATIVE ILEUS ON
LENGTH OF STAY IN COLECTOMY
Sarawate C, Dalal M
University of Illinois at Chicago, Chicago, IL, USA
Colectomy is a common surgical procedure known to be
associated with Postoperative Ileus (POI). POI leads to
inhibited bowel function following surgical procedures
and it delays discharge of hospital patients by affecting
patient’s tolerance to solid/liquid intake. Thus, POI can
potentially extend length of stay (LOS) and increase 
hospital costs in colectomy patients.
OBJECTIVES: To evaluate impact of POI on LOS and
determine factors that lead to POI in hospital patients
undergoing colectomy.
METHODS: Adult patients who underwent colectomy,
with/without POI were identiﬁed from cross-sectional
1999 National Hospital Discharge Survey (NHDS) using
ICD-9-CM code for surgical procedures and diagnosis
(457.1, 457.4 and 458). Hospital patients with cardiac,
respiratory, or urinary comorbidities were excluded.
Patient characteristics and LOS were compared between
patients with/without POI using student’s t-test. Patient
characteristics affecting development of POI were evalu-
ated using logistic regression. All analyses were conducted
using SAS version 8.0. Data were weighted to obtain
national estimates.
RESULTS: The mean LOS was 13.29 (+/- 8.74) vs. 7.49
(+/- 3.37) days in patients with/ without POI respectively.
The LOS in patients with POI was signiﬁcantly greater
than those without POI (p < 0.0001) after re-scaling
record weights. Patient characteristics of age, gender, race
and primary payer were not signiﬁcantly associated with
development of POI.
CONCLUSIONS: POI leads to signiﬁcant increase in
LOS of patients who underwent colectomy. We suspect
severity of illness and treatment characteristics to inter-
act with POI. However, data on these variables were not
available in the survey. Therefore, we could not detect 
a signiﬁcant association of the factors, considered in 
this study, on POI. Future research would be needed to
ascertain impact of severity of illness and treatment 
characteristics on POI.
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OBJECTIVES: This study investigates the extent to which
IBS imposes a ﬁnancial burden on an employer.
METHODS: Administrative claims data from a national,
Fortune 100 manufacturer that includes all medical, phar-
maceutical, and disability claims for the company’s
employees, spouses, dependents, and retirees (n >
100,000) were used for this analysis. IBS patients (n =
1,610) were identiﬁed using ICD-9-CM codes of individ-
uals aged 18 through 64 years, who received primary
treatment for IBS; or secondary treatment for IBS and
primary treatment for constipation or abdominal pain,
between 1996 and 1998. Over 93% (N = 1,509) of these
IBS patients were matched based on age, sex, zip code,
and employment status to control beneﬁciaries. Excluded
from both the IBS and control samples were patients
treated for malignant neoplasm of digestive organ 
and peritoneum, inﬂammatory bowel disease, Crohn’s
disease, ulcerative colitis, and diverticulitis. Direct
(medical and pharmaceutical) and indirect (disability and
medically-related work absence) costs of IBS patients and
controls were estimated using SAS, version 8.
RESULTS: On average, an IBS patient cost the employer
$1,251 more than an employee not treated for IBS
($4,527 versus $3,276; p < 0.0001). Direct medical costs
accounted for 83% of total costs associated with IBS.
Hospital outpatient costs accounted for the largest
portion; average hospital outpatient costs were $1,258
and $742 for IBS patients and controls, respectively 
(p < 0.0001). The average number of medical claims per
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IBS patient was 17.4 versus 10.9 for controls (p <
0.0001). The average number of prescriptions ﬁlled was
26.9 versus 19.2 for IBS patients and controls respectively 
(p < 0.0001). Medically-related work absence costs were
$301 and $176 for IBS patients and controls, respectively
(p < 0.0001).
CONCLUSIONS: IBS patients impose a signiﬁcant 
ﬁnancial burden on the employer, due to higher levels 
of medical and pharmaceutical care utilization and 
medically-related work absences compared to controls.
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A COST ANALYSIS OF DIAGNOSTIC AND
TREATMENT STRATEGIES IN PATIENTS WITH
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OBJECTIVES: Many patients with symptoms of pouch-
itis respond to empiric antibiotic treatment. An alternate
diagnostic strategy, endoscopic evaluation reserves antibi-
otics for those patients who truly have pouchitis (approx-
imately 55% of symptomatic patients). The goal of this
project was to compare the costs and cost-effectiveness of
different strategies of diagnosis and treatment of patients
with pouchitis symptoms.
METHODS: A decision-analytic model assessed the fol-
lowing strategies: empiric treatment with metronidazole,
empiric treatment with ciproﬂoxacin, empiric treatment
with metronidazole and then ciproﬂoxacin for non-
responders, endoscopy with histology, and endoscopy
with no histology. Data regarding the likelihood of pou-
chitis, diagnostic accuracy and precision of endoscopy,
and response to empiric therapy were derived from
several recent clinical studies. Redbook wholesale prices
and 2001 Medicare reimbursement rates served as cost
source data. The model was run to determine the least
costly strategy and the most cost-effective strategy using
the number of days during the study that a patient was
diagnosed and treated as the unit of effectiveness.
RESULTS: The empiric treatment with metronidazole
strategy was the least costly ($216) strategy, followed by
the test with no histology ($228), empiric treatment with
metronidazole and then ciproﬂoxacin for non-responders
($238), empiric treatment with ciproﬂoxacin ($284), and
endoscopy with histology ($342). In cost effectiveness
analysis, the test with no histology strategy cost $12 more
and was associated with diagnosis and treatment 7 
days earlier compared with the empiric treatment with
metronidazole strategy (incremental cost effectiveness
ratio $1.83 per additional day diagnosed and treated). All
other strategies were dominated. Sensitivity analysis
revealed that results were not sensitive to variation in
model parameters.
CONCLUSION: Empiric treatment with metronidazole
was the least costly strategy, but endoscopy with no his-
tology might be considered the most cost-effective since
it offers a substantial improvement in the time to 
diagnosis and treatment for little additional cost.
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OBJECTIVES: Recent randomized trials have demon-
strated that the use of IV PPI following endoscopic
therapy lowers 30-day re-bleeding rates in patients with
ulcers displaying high-risk stigmata. However, the cost-
effectiveness of, in addition, using IV PPI routinely from
the moment of initial presentation until the endoscopy is
carried out in all bleeding patients is unknown.
METHODS: We assessed the cost-effectiveness of start-
ing an IV infusion of pantoprazole (80-mg bolus followed
by 8mg/hr) in all patients presenting with an upper GI
bleed until endoscopy can be carried out. The analysis
was conducted by creating a decision tree model in Data
3.5. Assumptions of probabilities and costs were derived
from the literature, a local Canadian cost database, 
and a national Registry of patients with Upper 
Gastrointestinal Bleeding undergoing Endoscopy
(RUGBE). Differential costs were attributed to ulcer,
variceal, and non ulcer non variceal lesions. Efﬁcacy was
the proportion of patients without an episode of re-
bleeding. Threshold and sensitivity analyses were con-
ducted. The time horizon was 30 days following hospital
admission. Costs are in 2001 Canadian dollars.
RESULTS: Using the base-case analysis, the dominant
strategy was that of IV PPI following endoscopy as it 
displayed equal effectiveness at a lesser cost (average 
cost-effectiveness of $2,743 per patient who does not re-
bleed) when compared to a strategy of starting IV PPI on
all patients pre-endoscopy. When postulating increased
beneﬁt for patients who are subsequently found to be
bleeding from high or low risk ulcer lesions, variceal, or
non variceal non ulcer causes of bleeding, the results
remain unchanged across a reasonable range of clinical
assumptions both in one-way and multi-way sensitivity
analyses.
CONCLUSIONS: The use of IV PPI following ﬁndings of
urgent endoscopy appears to be the most cost-effective
approach when compared to initiating IV PPI in all 
bleeding patients prior to endoscopy.
